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Results After screening, 142 full-text articles were 
obtained, of which 22 met the eligibility criteria. A total 
of 43 different prognostic factors were investigated in the 
included studies, of which 17 were relevant to pre-treatment 
survival estimation. The prognostic factors most frequently 
associated with survival were the primary tumor and the per-
formance status. The prognostic factors most frequently not 
associated with survival were age, gender, number and loca-
tion of the SBM and the presence of a pathologic fracture.
Conclusions Prognostication for patients with SBM should 
be based on an accurate primary tumor classification, com-
bined with a performance score. The benefit of adding other 
prognostic factors is doubtful.
Keywords Spinal bone metastases · Prognostication · 
Systematic review
Introduction
Spinal bone metastases (SBM) are a frequently observed 
complication of malignant disease. Due to an increase in 
the survival times of patients with malignancies, the inci-
dence of SBM is expected to rise over the years [1, 2]. 
The majority of symptomatic SBM are caused by breast, 
prostate and lung cancer (56–74%) [3–5] and most com-
monly arise from the thoracic part of the spine (51–67%) 
[4, 6]. Patients present with pain due to destruction of 
bone tissue and/or neurologic complaints due to nerve root 
and/or spinal cord compression [7, 8]. Both radiothera-
peutical and surgical interventions are effective in treating 
these symptoms. However, due to the relatively short life 
expectancy of these patients, overtreatment is a common 
problem. Therefore, an accurate estimation of survival 
plays a pivotal role in selecting the appropriate treatment. 
Abstract 
Purpose For the selection of treatment in patients with 
spinal bone metastases (SBM), survival estimation plays a 
crucial role to avoid over- and under-treatment. To aid cli-
nicians in this difficult task, several prediction models have 
been developed, consisting of many different risk factors. 
The aim of this systematic review was to identify prognos-
tic factors that are associated with survival in patients with 
SBM to support development of predictive models.
Methods A systematic review was performed with focus 
on prognostic factors associated with survival in patients 
with SBM. Two reviewers independently selected studies 
for inclusion and assessed the risk of bias. A level of evi-
dence synthesis was performed for each prognostic factor. 
Inter-observer agreement for the risk of bias assessment was 
determined by the kappa-statistic.
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Survival estimation by clinicians has been shown to be 
too optimistic [9] and to provide an aid for this difficult 
task, several prediction models have been developed [4, 8, 
10, 11]. These models employ different sets of prognostic 
factors such as performance score, primary tumor and the 
presence of visceral metastases to stratify patients with 
SBM according to survival risk, enabling clinicians to 
select a more appropriate treatment. Several studies have 
been undertaken to assess the prognostic value of these 
models and the factors being used [12, 13]. The aim of 
this systematic review was to identify prognostic factors 
that are associated with survival in patients with spinal 
bone metastases in order to help guide development of 
predictive models.
Methods
This study was conducted according to the guidelines pro-
vided by the PRISMA statement.
Search strategy
The review protocol for this study was prospectively reg-
istered online at PROSPERO under registration number 
CRD42014006706 (http://www.crd.york.ac.uk/prospero). 
The search strategy was formulated in collaboration with a 
medical librarian to focus on the key terms survival, prog-
nostic factors and spinal bone metastases, or variations 
thereof. The electronic databases Medline, Embase, Web of 
Science, Cochrane and Cinahl were searched from January 
1999 up to September 2014. The complete search strategy 
is available as an online supplement.
Eligibility criteria
Both prospective and retrospective studies were eligible for 
inclusion if they met the following criteria: (1) Sample size 
of at least 100 patients with spinal bone metastases from 
solid tumors (i.e., no hematological malignancies); (2) The 
study did not focus on one single primary malignancy; (3) 
Prognostic factors for survival were assessed by means of 
a multivariate analysis; (4) Studies were published in the 
English, German or Dutch language. If studies were derived 
from identical databases, the most comprehensive study was 
selected; separately published subgroup analyses were disre-
garded. Eligibility of studies was assessed by two independ-
ent review authors (W. J. and L. B.). A consensus meeting 
was planned to resolve disagreements. If disagreements 
persisted, a third review author (P. D. S. D.) was consulted.
Risk of bias
The risk of bias was assessed according to the guidelines 
provided by Hayden et al. [14]. In short, six main sources of 
potential bias (study participation, study attrition, prognos-
tic factor measurement, outcome measurement, confounding 
and analysis) were assessed using a 29-item checklist. The 
six sources of bias were scored as being ‘high; 3 points’, 
‘moderate; 2 points’, or ‘low; 1 point’. Therefore, the total 
number of points for each study ranged from 6 to 18, with 
a cut-off set at a maximum of 50% (≤ 9 points) for distin-
guishing a low risk of bias study from a high risk of bias 
study. Two review authors (W. J. and L. B.) independently 
scored the risk of bias for each study. A consensus meet-
ing was planned to resolve disagreements. If disagreements 
persisted, a third review author (P. D. S. D.) decided on the 
risk of bias.
Data extraction
The data extracted from eligible studies consisted of the 
design, source of funding, setting, sample size, duration, 
inclusion and exclusion criteria, all prognostic factors inves-
tigated, duration of follow-up and results. If similar prognos-
tic factors were investigated by different means, they were 
combined for the level of evidence analysis. For instance, 
the prognostic factor Performance status was assessed by 
means of the Karnofsky score [15] or the Eastern Coopera-
tive Oncology Group score [16]. Other combined prognostic 
factors were Neurologic deficit; consisting of the Frankel 
score [17] and ambulatory status, as well as the variable 
Primary tumor; consisting of several different sub classifica-
tions. Prognostic factors such as Age and Number or location 
of SBM were also combined irrespective of any differences 
in cut-off points used. Two review authors (O. H and L. B.) 
extracted the data on standardized forms. When consensus 
could not be reached, a third review author (P. D. S. D.) was 
consulted.
Statistical analysis
Statistical pooling of the results was not possible; therefore 
a level of evidence synthesis was performed for each prog-
nostic factor. The levels of evidence were defined as follows: 
[18, 19].
• Strong evidence: consistent findings (≥ 75%) in multiple 
high-quality cohorts.
• Moderate evidence: consistent findings (≥ 75%) in multi-
ple cohorts, of which only one cohort was of high quality.
• Limited evidence: findings of one high-quality cohort, or 
consistent (≥ 75%) findings in one or more low-quality 
cohorts.
801Eur Spine J (2018) 27:799–805 
1 3
• Inconclusive: inconsistent findings (< 75%) irrespective 
of study quality.
Inter-observer agreement for the risk of bias assessment 
was determined by the kappa-statistic [20]. All analyses 
were performed using SPSS 20.0, Armonk NY, IBM Corp.
Results
Study selection
The initial search yielded 4676 results (Medline n = 1996; 
Embase n = 1389; Web of Science n = 1092; Cochrance 
n = 145; Cinahl n = 54). A total of 1687 duplicates were 
removed, leaving 2989 studies. After screening, 142 full-text 
articles were obtained, of which 120 did not meet the eligi-
bility criteria: 33 studies were based on duplicate cohorts, 
49 studies focused on a single primary tumor, 23 studies 
had less than 100 participants, 13 studies did not perform a 
multivariate analysis and two studies were excluded based 
on language. In total, 22 studies were included (Fig. 1) 
[3–6, 8, 21–37]. During the selection process, the reviewers 
disagreed on seven inclusions. Consensus was reached for 
all studies.
Study characteristics
The characteristics of the 22 included studies are presented 
in Table 1. Seven studies were based on prospectively col-
lected data and the remaining 15 inclusions were retrospec-
tive studies. The population of seven studies consisted of 
surgically treated patients only, whereas five studies were 
based on patients treated with radiotherapy only. Nine stud-
ies consisted of a mixed population and the treatment details 
of one study were not reported. Duration of follow-up was 
reported in nine studies and ranged from 8 to 72 months. 
Median duration of the period of recruitment was 8 years 
and ranged from 1 to 20 years.
Risk of bias
Of the 22 included studies, agreement on the overall risk 
of bias was obtained for 18 (82%). Consensus was reached 
for the remaining four studies. Inter-observer agreement for 
the overall risk of bias was substantial (kappa 0.62). Lower 
levels of agreement were mainly observed in the categories 
study participation (kappa 0.19) and confounding (kappa 
− 0.13).
Prognostic factors levels of evidence
A total of 43 different prognostic factors were investigated 
in the 22 included studies. Seven prognostic factors per-
tained to post-treatment details and four prognostic factors 
were specific to the received treatment of the patients in 
the cohort. These prognostic factors were therefore not con-
sidered relevant to pre-treatment estimation of survival and 
were excluded. Fifteen prognostic factors were analyzed 
only once. Because the level of evidence for these factors 
by definition could not exceed the category ‘limited’ they are 
not mentioned in the results, but are presented in an online 
supplement. The remaining seventeen prognostic factors are 
detailed in Table 2. Prognostic factors influencing survival 
in a certain study are mentioned in the column ‘positive 
association’ and studied prognostic factors not influencing 
survival are mentioned in the column ‘no association’.
Strong evidence for a positive association with survival 
was found for the primary tumor, performance status and 
the American Society of Anesthesiologists (ASA) classifica-
tion [38]. Strong evidence for no association with survival 
was found for gender, age, number of spinal bone metasta-
ses, location of spinal bone metastases, and the presence of 
a pathologic fracture. The evidence was inconclusive for 
visceral metastases, neurologic deficit, the interval between 






































Fig. 1  Flowchart study selection process
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Table 2  Level of evidence for investigated prognostic factors. Numbers refer to study identification from Table 1
Studies with a low risk of bias are in bold
ASA American Society of Anesthesiologists; SBM spinal bone metastases
Prognostic factor Positive association No association Level of evidence
Primary tumor 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 17, 
18, 20, 21, 22
13, 16, 19 Strong—86%
Performance status 2, 3, 8, 9, 11, 12, 13, 17, 18, 19, 20, 21, 22 14 Strong—93%
ASA classification 11, 19 Strong—100%
Age 6, 9, 13 2, 7, 10, 11, 12, 14, 15, 16, 17, 18, 19, 22 Strong—80%
Gender 2, 8, 18 7, 9, 10, 11, 12, 13, 14, 16, 17, 19, 22 Strong—79%
Number SBM 21 2, 11, 12, 14, 16, 17, 18, 19, 20, 22 Strong—91%
Location SBM 8 2, 7, 10, 11, 16, 19, 20, 22 Strong—89%
Pathologic fracture 7,11,12 Strong—100%
Visceral metastases 3, 9, 12, 14, 15, 17, 18, 19, 20, 21, 22 2, 7, 11, 13 Inconclusive—73%
Neurologic deficit 1, 4, 5, 7, 18, 21 2, 12, 14, 16, 17, 19, 20, 22 Inconclusive—57%
Interval diagnosis 1, 13, 14, 18 15, 16 Inconclusive—67%
Extraspinal bone metastases 14, 17, 18 12, 19, 20, 21, 22 Inconclusive—63%
Number bone metastases 9, 15 3, 21 Inconclusive—50%
Pain 4, 11 14 Inconclusive—67%
Sphincter function 5 7, 11 Inconclusive—67%
Weight loss 11 19 Inconclusive—50%
Cardiovascular disease 11 19 Inconclusive—50%
Table 1  Characteristics of the 22 included studies
SUR patients treated with surgery; RTC patients treated with radiotherapy or conservative therapy; NR not reported
Study ID Author, year, country Study type No. patients % SUR/RTC Follow-
up 
(months)




1 Helweg, 2000, Denmark Prospective 153 0/100 NR 1996–1999 4 High
2 Riegel, 2002, Germany Retrospective 139 NR NR 1990–1997 8 High
3 Linden, 2004, Netherlands Prospective 342 0/100 16 1996–1998 3 Low
4 Hosono, 2005, Japan Retrospective 176 100/0 23 1985–2001 16 High
5 Ibrahim, 2008, Interna-
tional
Prospective 223 100/0 NR 2002–2003 2 High
6 Chi, 2009, USA Prospective 101 50/50 8 1992–2002 11 High
7 Arrigo, 2011, USA Retrospective 200 100/0 NR 1999–2009 11 Low
8 Bartels, 2011, Interna-
tional
Retrospective 567 9/91 NR 1996–2008 13 Low
9 Mizumoto, 2011, Japan Retrospective 603 0/100 19 2002–2007 5 Low
10 Park, 2011, Korea Retrospective 103 100/0 26 2001–2008 8 High
11 Pointillart, 2011, France Prospective 142 83/17 NR 2005–2007 3 Low
12 Wibmer, 2011, Austria Retrospective 254 25/75 36 1998–2006 9 Low
13 Chao, 2012, USA Retrospective 174 0/100 9 2006–2009 4 High
14 Kataoka, 2012, Japan Retrospective 143 50/50 21 1990–2008 19 Low
15 Tancioni, 2012, Italy Retrospective 151 100/0 NR 2004–2007 4 High
16 Yang, 2012, Korea Retrospective 217 100/0 NR 2001–2009 9 Low
17 Balain, 2013, UK Prospective 199 52/48 NR 2010–NR NR High
18 Rades, 2013, Germany Retrospective 2029 0/100 NR 1992–2011 20 High
19 Tabouret, 2013, France Retrospective 148 100/0 24 2004–2010 7 Low
20 Bollen, 2014, Netherlands Retrospective 1043 5/95 72 2001–2010 10 Low
21 Morgen, 2014, Denmark Prospective 544 16/84 NR 2011 1 High
22 Yeung, 2014, Hong Kong Retrospective 128 46/54 NR 2001–2011 11 High
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SBM, the presence of extraspinal bone metastases, total 
number of bone metastases, pain, sphincter function, weight 
loss and cardiovascular disease.
Discussion
In this systematic review, it is shown that the primary tumor, 
performance status and the ASA classification are associated 
with survival in patients with spinal bone metastases. Age, 
gender, number of SBM, location of SBM and the presence 
of a pathologic fracture are most likely not associated with 
survival.
Even though the eligibility criteria for this study were 
strict, several limitations were observed. Firstly, 68% of the 
included studies were conducted retrospectively and 55% of 
the studies consisted of populations that were treated either 
only with surgery or only with radiotherapy. This increased 
the risk of bias and therefore the quality of our results. Also, 
the way the studies evaluated the prognostic factors was het-
erogeneous and several different cut-off points were used.
The primary tumor was investigated as a potential prog-
nostic factor in all but one study. Even though several dif-
ferent classifications were used, it was found to be associ-
ated with survival in 86% of the included studies, leaving 
no doubt that an accurate primary tumor classification is 
required for prognostication in patients with spinal bone 
metastases. The same applies to the performance status, 
with a positive association rate of 93%. Irrespective of 
which specific score is used, it provides essential informa-
tion for accurate prognostication. The ASA classification 
was investigated in two studies with a low risk of bias and 
both found a positive association with survival. Because 
it is rather similar to the performance status, it remains to 
be seen whether there is a significant benefit to including 
both factors in a prognostic model.
Age was found not to be associated with survival in 80% 
of the included studies. Considering the fact that a perfor-
mance score generally provides a much better measure of a 
patient’s health—and therefore prognosis—than age does, 
it is not unexpected that this variable is not significantly 
associated with survival in a multivariate analysis. Gen-
der also was not associated with survival, with a rate of 
79%. Breast and prostate cancer make up a large percent-
age of the populations in the included studies. Since they 
are gender specific, it is likely that any potential effect of 
gender is corrected on multivariate analysis. Gender might 
play a role in SBM prognostication for certain primary 
cancers with a more even distribution, such as lung cancer. 
Number and location of the SBM, as well as the presence 
of pathologic fractures, had no effect on survival in the 
majority of the included studies. Even though these factors 
are important to consider when deciding on treatment—for 
instance determining extent of radiation field or levels of 
surgical fixation—they most likely do not need to be con-
sidered with respect to survival.
The rate of positive association for the presence of vis-
ceral metastases was 73%, meaning the level of evidence 
was only just inconclusive. A recent study that stratified 
the risk factor analysis based on the primary tumor clas-
sification found that the effect of visceral metastases on 
survival changed between different tumor categories [4]. 
The survival of patients with a fast growing, aggressive 
tumor was not affected by visceral metastases, whereas 
patients with a slow growing tumor did have a significantly 
shorter survival when visceral metastases were present. 
The included low risk of bias studies that found a posi-
tive association had, on average, 10% more breast cancer 
patients in their population than studies that did not find an 
association. This difference in composition of the popula-
tion might explain the different findings in these studies. 
The prognostic factor neurologic deficit consisted of two 
variables; ambulatory status and the Frankel classification. 
Because of the interaction with the performance status of 
a patient, this variable can be difficult to obtain, especially 
retrospectively. Even though it is an important variable to 
consider when deciding on type of treatment, it is unclear 
whether this variable plays a role in estimating survival.
A recently published meta-analysis by Luksanapruksa 
et al. [39] aimed to assess prognostic factors in patients with 
spinal bone metastases. Seventeen poor prognostic factors 
were identified, including the primary tumor classification 
and performance score. Contrary to the current study, how-
ever, Luksanapruksa et al. also found items such as number 
of SBM, presence of other bone metastases and ambulatory 
status important prognostic factors. This is most likely due 
to the fact that all studies by Rades et al. were included in 
the analysis. Since the same cohort was used repeatedly, the 
effects were somewhat amplified. Also, the large measure 
of heterogeneity found in most of the pooled risk factors 
indicate that a meta-analysis might not be the most ideal 
approach to addressing this topic.
In conclusion, prognostication for patients with SBM 
should be based on an accurate primary tumor classification, 
combined with a performance score. The added benefit of 
including the ASA classification should be studied further, 
as should the influence of visceral metastases and the pres-
ence of neurologic deficit.
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